Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries XBI's Holdings Could Mean 37% Gain Potential By: ETF Channel August 30, 2018 at 07:38 AM EDT Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $136.66 per unit. Read More >> Related Stocks: Apellis Pharmaceuticals Inc Five Prime Thera Puma Biotechnology S&P Biotech SPDR Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
XBI's Holdings Could Mean 37% Gain Potential By: ETF Channel August 30, 2018 at 07:38 AM EDT Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR S&P Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $136.66 per unit. Read More >> Related Stocks: Apellis Pharmaceuticals Inc Five Prime Thera Puma Biotechnology S&P Biotech SPDR